Ally Bridge Group »

Arcutis Biotherapeutics shares owned by Ally Bridge Group

Quarter-by-quarter ownership of Arcutis Biotherapeutics (ARQT) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in Arcutis Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Arcutis Biotherapeutics held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arcutis Biotherapeutics by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $4.4M 233k 18.85

More positions owned by Ally Bridge Group

Soleno Therapeutics (SLNO)
Replimune Group Call Option (REPL)
Madrigal Pharmaceuticals (MDGL)
Compass Pathways Sponsored Ads (CMPS)
Atai Beckley Nv SHS (ATAI)
Ascendis Pharma A/s - Sponsored Adr (ASND)
Lenz Therapeutics (LENZ)
Taysha Gene Therapies Com Shs (TSHA)
Amylyx Pharmaceuticals (AMLX)
Eupraxia Pharmaceuticals (EPRX)
Praxis Precision Medicines I Com New Call Option (PRAX)
Monopar Therapeutics Com New (MNPR)
Arcutis Biotherapeutics (ARQT)
Mind Medicine Mindmed Com New (MNMD)
Tarsus Pharmaceuticals (TARS)

View all positions for Ally Bridge Group

Top funds holding Arcutis Biotherapeutics

Jennison Associates
Rubric Capital Management
Suvretta Capital Management
Frazier Life Sciences Management
BlackRock
Vanguard Group
Polar Capital Holdings
State Street Corporation
Gilder, Gagnon, Howe & Co
Morgan Stanley
UBS Group
Geode Capital Management
Henderson Group
Franklin Resources
Pivotal bioVenture Partners Investment Advisor

View all funds holding Arcutis Biotherapeutics